Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Since lapatinib inhibits both EGFR and HER2 receptors, it is an attractive agent
for the treatment of esophageal and GEJ tumors.
PURPOSE: Lapatinib is currently approved for HER2 positive metastatic breast cancer in
combination with capecitabine or letrozole. It is hoped that by giving lapatinib and
carboplatin and paclitaxel together, their combined effects will further slow or stop the
cancer cells from growing.